In addition, we consider the three PRAME TCRs (DSK3PRAME/QLL/A2, 16.3C1PRAME/LYV/A24 and 8.10C4PRAME/SPS/B7) and CTCFL TCR (39.2E12CTCFL/KLH/A2) to be promising candidates for the treatment of patients with ovarian cancer, and also for other PRAME or CTCFL expressing cancers. Here, CTCFL is linked to ovarian carcinoma.